Patent · US Active

N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

USRE48285E1 · kind E1 · reissue

2Cited by

11References

26Claims

0Family size

Assignee

Sierra Oncology, Inc. · US

Inventors

Brandon Heath Brown · Burlingame, US
Ernest A. Carra · Foster City, US
Jeffrey N. Hemenway · San Mateo, US
Henry Morrison · Dublin, US
Troy Reynolds · San Francisco, US
Bing Shi · Redwood City, US
Dimitrios Stefanidis · Mountain View, US
Fang Wang · Foster City, US
Matthew Robert Warr · Madison, US
James Andrew Whitney · Guilford, US
Yan Xin · Redwood City, US

Key dates

Filing date	Oct 18, 2018
Grant date	Oct 27, 2020
Priority date	—
Expiry date	Oct 18, 2038

Classification

Technology area (CPC —)General

Abstract

The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.